Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance.
View/ Open
File version
Accepted Manuscript (AM)
Author(s)
Cochrane, T
Campbell, BA
Gangatharan, SA
Latimer, M
Khor, R
Christie, Drh
Gilbertson, M
Ratnasingam, S
Palfreyman, E
Lee, HP
Trotman, J
Hertzberg, M
Dickinson, M
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All ...
View more >The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All rights reserved.
View less >
View more >The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All rights reserved.
View less >
Journal Title
Internal Medicine Journal
Copyright Statement
© 2021 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance, Internal Medicine Journal, 2021, which has been published in final form at https://doi.org/10.1111/imj.15503. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
Note
This publication has been entered in Griffith Research Online as an advanced online version.
Subject
Public health
Cardiovascular medicine and haematology
Clinical sciences
HL
Hodgkin Lymphoma
PET adapted
chemotherapy
radiotherapy